Skip to content

Clinical trials

Completed Phase 1 Lymphoma, Large-Cell, Anaplastic trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma, Large-Cell, Anaplastic Phase: Phase 1 Status: Completed Clear all

105 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20015
20028
20033
20045
20052
20068
20078
20086
20095
20107
20115
20123
20135
20142
20171
20191
20211
20221

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed105

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)31
National Institutes of Health Clinical Center (CC)7
Memorial Sloan Kettering Cancer Center5
Seagen Inc.4
Case Comprehensive Cancer Center3
City of Hope Medical Center3
Children's Oncology Group2
M.D. Anderson Cancer Center2
Millennium Pharmaceuticals, Inc.2
NYU Langone Health2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma, Large-Cell, Anaplastic105
Immunoblastic Lymphadenopathy81
Lymphoma, Large B-Cell, Diffuse81
Hodgkin Disease80
Lymphoma, Follicular79
Lymphoma, Mantle-Cell78
Burkitt Lymphoma77
Lymphoma, B-Cell, Marginal Zone76
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma76
Leukemia, Lymphocytic, Chronic, B-Cell75

Trials

Showing 1 to 25 of 105. Each trial links to its page on Pharma Observatory.

5 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.